Literature DB >> 24277027

Multicenter study of anidulafungin and micafungin MIC distributions and epidemiological cutoff values for eight Candida species and the CLSI M27-A3 broth microdilution method.

M A Pfaller1, A Espinel-Ingroff, B Bustamante, E Canton, D J Diekema, A Fothergill, J Fuller, G M Gonzalez, J Guarro, C Lass-Flörl, S R Lockhart, E Martin-Mazuelos, J F Meis, L Ostrosky-Zeichner, T Pelaez, G St-Germain, J Turnidge.   

Abstract

Since epidemiological cutoff values (ECVs) using CLSI MICs from multiple laboratories are not available for Candida spp. and the echinocandins, we established ECVs for anidulafungin and micafungin on the basis of wild-type (WT) MIC distributions (for organisms in a species-drug combination with no detectable acquired resistance mechanisms) for 8,210 Candida albicans, 3,102 C. glabrata, 3,976 C. parapsilosis, 2,042 C. tropicalis, 617 C. krusei, 258 C. lusitaniae, 234 C. guilliermondii, and 131 C. dubliniensis isolates. CLSI broth microdilution MIC data gathered from 15 different laboratories in Canada, Europe, Mexico, Peru, and the United States were aggregated to statistically define ECVs. ECVs encompassing 97.5% of the statistically modeled population for anidulafungin and micafungin were, respectively, 0.12 and 0.03 μg/ml for C. albicans, 0.12 and 0.03 μg/ml for C. glabrata, 8 and 4 μg/ml for C. parapsilosis, 0.12 and 0.06 μg/ml for C. tropicalis, 0.25 and 0.25 μg/ml for C. krusei, 1 and 0.5 μg/ml for C. lusitaniae, 8 and 2 μg/ml for C. guilliermondii, and 0.12 and 0.12 μg/ml for C. dubliniensis. Previously reported single and multicenter ECVs defined in the present study were quite similar or within 1 2-fold dilution of each other. For a collection of 230 WT isolates (no fks mutations) and 51 isolates with fks mutations, the species-specific ECVs for anidulafungin and micafungin correctly classified 47 (92.2%) and 51 (100%) of the fks mutants, respectively, as non-WT strains. These ECVs may aid in detecting non-WT isolates with reduced susceptibility to anidulafungin and micafungin due to fks mutations.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24277027      PMCID: PMC3910887          DOI: 10.1128/AAC.02020-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

1.  Sensititre YeastOne caspofungin susceptibility testing of Candida clinical isolates: correlation with results of NCCLS M27-A2 multicenter study.

Authors:  Emilia Cantón; Javier Pemán; Miguel Gobernado; Elena Alvarez; Fernando Baquero; Ramón Cisterna; Joaquina Gil; Estrella Martín-Mazuelos; Carmen Rubio; Aurora Sánchez-Sousa; Carmen Serrano
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

2.  Statistical methods for establishing quality control ranges for antibacterial agents in Clinical and Laboratory Standards Institute susceptibility testing.

Authors:  John Turnidge; Gerry Bordash
Journal:  Antimicrob Agents Chemother       Date:  2007-04-16       Impact factor: 5.191

3.  Potential confusion regarding the term 'resistance' in epidemiological surveys.

Authors:  S Simjee; P Silley; H O Werling; R Bywater
Journal:  J Antimicrob Chemother       Date:  2007-11-20       Impact factor: 5.790

Review 4.  Setting and revising antibacterial susceptibility breakpoints.

Authors:  John Turnidge; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2007-07       Impact factor: 26.132

5.  Clinical evaluation of the Sensititre YeastOne colorimetric antifungal panel for antifungal susceptibility testing of the echinocandins anidulafungin, caspofungin, and micafungin.

Authors:  M A Pfaller; V Chaturvedi; D J Diekema; M A Ghannoum; N M Holliday; S B Killian; C C Knapp; S A Messer; A Miskov; R Ramani
Journal:  J Clin Microbiol       Date:  2008-05-07       Impact factor: 5.948

6.  Echinocandin susceptibility testing of Candida species: comparison of EUCAST EDef 7.1, CLSI M27-A3, Etest, disk diffusion, and agar dilution methods with RPMI and isosensitest media.

Authors:  Maiken Cavling Arendrup; Guillermo Garcia-Effron; Cornelia Lass-Flörl; Alicia Gomez Lopez; Juan-Luis Rodriguez-Tudela; Manuel Cuenca-Estrella; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2009-11-02       Impact factor: 5.191

7.  International surveillance of Candida spp. and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2003).

Authors:  Shawn A Messer; Ronald N Jones; Thomas R Fritsche
Journal:  J Clin Microbiol       Date:  2006-05       Impact factor: 5.948

Review 8.  In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature.

Authors:  Ana Espinel-Ingroff
Journal:  Rev Iberoam Micol       Date:  2003-12       Impact factor: 1.044

9.  Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp.

Authors:  M A Pfaller; L Boyken; R J Hollis; J Kroeger; S A Messer; S Tendolkar; R N Jones; J Turnidge; D J Diekema
Journal:  J Clin Microbiol       Date:  2009-11-18       Impact factor: 5.948

10.  Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America.

Authors:  Peter G Pappas; Carol A Kauffman; David Andes; Daniel K Benjamin; Thierry F Calandra; John E Edwards; Scott G Filler; John F Fisher; Bart-Jan Kullberg; Luis Ostrosky-Zeichner; Annette C Reboli; John H Rex; Thomas J Walsh; Jack D Sobel
Journal:  Clin Infect Dis       Date:  2009-03-01       Impact factor: 9.079

View more
  20 in total

1.  Use of anidulafungin as a surrogate marker to predict susceptibility and resistance to caspofungin among 4,290 clinical isolates of Candida by using CLSI methods and interpretive criteria.

Authors:  Michael A Pfaller; Daniel J Diekema; Ronald N Jones; Mariana Castanheira
Journal:  J Clin Microbiol       Date:  2014-06-20       Impact factor: 5.948

2.  Candida fermentati as a cause of persistent fungemia in a preterm neonate successfully treated by combination therapy with amphotericin B and caspofungin.

Authors:  Noura Al-Sweih; Suhail Ahmad; Leena Joseph; Seema Khan; Sandhya Vayalil; Rachel Chandy; Ziauddin Khan
Journal:  J Clin Microbiol       Date:  2015-01-07       Impact factor: 5.948

Review 3.  Establishment and Use of Epidemiological Cutoff Values for Molds and Yeasts by Use of the Clinical and Laboratory Standards Institute M57 Standard.

Authors:  Shawn R Lockhart; Mahmoud A Ghannoum; Barbara D Alexander
Journal:  J Clin Microbiol       Date:  2017-02-15       Impact factor: 5.948

Review 4.  Echinocandin resistance, susceptibility testing and prophylaxis: implications for patient management.

Authors:  David S Perlin
Journal:  Drugs       Date:  2014-09       Impact factor: 9.546

5.  Multilaboratory study of epidemiological cutoff values for detection of resistance in eight Candida species to fluconazole, posaconazole, and voriconazole.

Authors:  A Espinel-Ingroff; M A Pfaller; B Bustamante; E Canton; A Fothergill; J Fuller; G M Gonzalez; C Lass-Flörl; S R Lockhart; E Martin-Mazuelos; J F Meis; M S C Melhem; L Ostrosky-Zeichner; T Pelaez; M W Szeszs; G St-Germain; L X Bonfietti; J Guarro; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2014-01-13       Impact factor: 5.191

6.  Multicenter Study of Method-Dependent Epidemiological Cutoff Values for Detection of Resistance in Candida spp. and Aspergillus spp. to Amphotericin B and Echinocandins for the Etest Agar Diffusion Method.

Authors:  A Espinel-Ingroff; M Arendrup; E Cantón; S Cordoba; E Dannaoui; J García-Rodríguez; G M Gonzalez; N P Govender; E Martin-Mazuelos; M Lackner; C Lass-Flörl; M J Linares Sicilia; M A Rodriguez-Iglesias; T Pelaez; R K Shields; G Garcia-Effron; J Guinea; M Sanguinetti; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2016-12-27       Impact factor: 5.191

7.  Candida lusitaniae MICs to the echinocandins are elevated but FKS-mediated resistance is rare.

Authors:  Shawn R Lockhart; Cau D Pham; Randall J Kuykendall; Carol B Bolden; Angela A Cleveland
Journal:  Diagn Microbiol Infect Dis       Date:  2015-08-28       Impact factor: 2.803

8.  Hot topics in antifungal susceptibility testing: A new drug, a bad bug, sweeping caspofungin testing under the rug, and solving the ECV shrug.

Authors:  Shawn R Lockhart; Elizabeth L Berkow
Journal:  Clin Microbiol Newsl       Date:  2016-07

9.  Multicenter study of epidemiological cutoff values and detection of resistance in Candida spp. to anidulafungin, caspofungin, and micafungin using the Sensititre YeastOne colorimetric method.

Authors:  A Espinel-Ingroff; M Alvarez-Fernandez; E Cantón; P L Carver; S C-A Chen; G Eschenauer; D L Getsinger; G M Gonzalez; N P Govender; A Grancini; K E Hanson; S E Kidd; K Klinker; C J Kubin; J V Kus; S R Lockhart; J Meletiadis; A J Morris; T Pelaez; G Quindós; M Rodriguez-Iglesias; F Sánchez-Reus; S Shoham; N L Wengenack; N Borrell Solé; J Echeverria; J Esperalba; E Gómez-G de la Pedrosa; I García García; M J Linares; F Marco; P Merino; J Pemán; L Pérez Del Molino; E Roselló Mayans; C Rubio Calvo; M Ruiz Pérez de Pipaon; G Yagüe; G Garcia-Effron; J Guinea; D S Perlin; M Sanguinetti; R Shields; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2015-08-17       Impact factor: 5.191

10.  Multicenter Comparison of the Etest and EUCAST Methods for Antifungal Susceptibility Testing of Candida Isolates to Micafungin.

Authors:  M-E Bougnoux; E Dannaoui; I Accoceberry; A Angoulvant; E Bailly; F Botterel; S Chevrier; T Chouaki; M Cornet; F Dalle; A Datry; A Dupuis; A Fekkar; J P Gangneux; J Guitard; C Hennequin; Y Le Govic; P Le Pape; D Maubon; S Ranque; M Sautour; B Sendid; J Chandenier
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.